Tinostamustine included in Ph 2/3 GBM AGILE adaptive clinical trial for GBM patients September 23, 2025
Patients With Aggressive Brain and Advanced Liver Cancers Treated with PIC monotherapy Reach Five Years of Durable RFS September 23, 2025
European Commission Approves VORANIGO® (vorasidenib) for Grade 2 IDH-Mutant Glioma September 23, 2025
Initial Data Shows 100% Disease Control in all 5 Recurrent GBM patients and Near CR in 2, Treated With ANKTIVA® + Optune Gio® Device September 3, 2025
NeOnc Technologies Awarded $2.5M in NIH STTR Grants to Advance NEO212 in Gliomas and Leukemia in Ph 2 trials August 12, 2025
U.S. FDA Approves Modeyso™ (dordaviprone) for Recurrent H3 K27M-mutant Diffuse Midline Glioma August 11, 2025
Positive CHMP Opinion for VORANIGO® (vorasidenib) for the Treatment of Adults and Adolescents with Grade 2 IDH-mutant Diffuse Glioma July 29, 2025
Breakthrough Therapy Designation application for oral gallium maltolate (GaM) in refractory brain tumors voluntarily withdrawn and resubmitted June 24, 2025
Patient with a grade 4, IDH-mutant, MGMT-methylated glioma remains alive and progression-free for four years upon treatment with the INB-200 in GBM trial June 17, 2025
Positive opinion for Orphan Medicinal Product Designation in the EU for GLIX1 in glioma June 10, 2025
First Patient Dosed in TNG456 Ph 1/2 Trial in Patients With MTAP-deleted GBM and Other Solid Tumors May 27, 2025
